The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jan. 22, 4:20 PM

Slide #1. Precigen, Inc. Secondary Offering

Company: Precigen, Inc. (NASDAQ:PGEN)
Date announced: 1/21/2021
Shares Offered: 15,000,000
Date of Pricing: 1/22/2021
Price Per Share: $7.50
Secondary Offering Details: Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of shares of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. -updated 1/22- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $112.5 million, excluding any exercise of the underwriters' option. The offering is expected to close on January 26, 2021, subject to customary closing conditions.

Precigen is a biopharmaceutical company. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is focusing on various product candidates through clinical trials, including UltraCAR-T therapies PRGN-3005, which targets the Mucin 16 antigen on the cell surface of ovarian and other peritoneal cancers, and PRGN-3006, which targets the CD33 antigen on the cell surface of acute myeloid leukemia, blasts, as well as AG013 and AG019, which are being investigated for the treatment of oral mucositis, and recent-onset type 1 diabetes mellitus, respectively.

PGEN SEC Filing Email Alerts Service

Open the PGEN Page at The Online Investor »

Company Name: 
Precigen Inc
Website: 
www.dna.com
Sector: 
Biotechnology
Number of ETFs Holding PGEN: 
30
Total Market Value Held by ETFs: 
$113.54M
Total Market Capitalization: 
$1.75B
% of Market Cap. Held by ETFs: 
6.51%
 

Open the PGEN Page at The Online Investor (in a new window) »

List of Secondary Stock Offerings in this Slideshow:

1/13/2021:
Company: Evoke Pharma, Inc. (EVOK)
Shares Offered: 5,000,000
More: offering details »

1/14/2021:
Company: Inuvo, Inc. (INUV)
Shares Offered: 13,333,334
More: offering details »

1/15/2021:
Company: Lantern Pharma (LTRN)
Shares Offered: 4,285,715
More: offering details »

1/15/2021:
Company: ProPhase Labs, Inc. (PRPH)
Shares Offered: 3,000,000
More: offering details »

1/19/2021:
Company: TCR2 Therapeutics Inc. (TCRR)
Shares Offered: 4,590,164
More: offering details »

1/19/2021:
Company: Athira Pharma, Inc. (ATHA)
Shares Offered: 4,000,000
More: offering details »

1/19/2021:
Company: Aclaris Therapeutics, Inc. (ACRS)
Shares Offered: 5,483,714
More: offering details »

1/19/2021:
Company: Editas Medicine, Inc. (EDIT)
Shares Offered: 3,500,000
More: offering details »

1/19/2021:
Company: Fulcrum Therapeutics, Inc. (FULC)
Shares Offered: 4,000,000
More: offering details »

1/19/2021:
Company: AcelRx Pharmaceuticals, Inc. (ACRX)
Shares Offered: 14,500,000
More: offering details »

1/19/2021:
Company: Passage Bio, Inc. (PASG)
Shares Offered: 7,000,000
More: offering details »

1/19/2021:
Company: CareDx, Inc. (CDNA)
More: offering details »

1/19/2021:
Company: Merus N.V. (MRUS)
More: offering details »

1/19/2021:
Company: Chimerix, Inc. (CMRX)
More: offering details »

1/19/2021:
Company: Bionano Genomics, Inc. (BNGO)
Shares Offered: 33,333,350
More: offering details »

1/19/2021:
Company: CytomX Therapeutics, Inc. (CTMX)
More: offering details »

1/19/2021:
Company: Cryoport, Inc. (CYRX)
More: offering details »

1/19/2021:
Company: Document Security Systems, Inc. (DSS)
Shares Offered: 6,666,666
More: offering details »

1/20/2021:
Company: Lithium Americas Corp. (LAC.CA)
Shares Offered: 15,909,091
More: offering details »

1/20/2021:
Company: Invitae Corporation (NVTA)
More: offering details »

1/20/2021:
Company: INOVIO Pharmaceuticals, Inc. (INO)
Shares Offered: 17,700,000
More: offering details »

1/20/2021:
Company: OncoSec Medical Incorporated (ONCS)
Shares Offered: 7,711,284
More: offering details »

1/20/2021:
Company: Dyne Therapeutics, Inc. (DYN)
Shares Offered: 6,000,000
More: offering details »

1/21/2021:
Company: Global Ship Lease, Inc. (GSL)
Shares Offered: 5,400,000
More: offering details »

1/21/2021:
Company: Precigen, Inc. (PGEN)
Shares Offered: 15,000,000
More: offering details »

Quotes delayed 20 minutes



Buy (3.00 out of 4)
29th percentile
(ranked lower than approx. 71% of all stocks covered)

Analysts' Target Price:
PGEN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.